TP53 and neoplasm: In the present study, based on the information that p53 mutations are not common in estrogen-responsive tumors (only 20% in breast cancers) [46], we tried to reactivate the p53 signaling through its liberation from mortalin–p53 complex shuttle freely to the nucleus to execute its tumor-suppression duties as a transcription factor.